Payment overview · 2025
General Payments
$1,597.27
67 reported records · 14 companies
Healthcare provider profile · identity verified
Phuong Lien Tran, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CHICAGO, IL · NPI 1821137142
Verified facts
What the public records show
CMS Open Payments records show Phuong Lien Tran, M.D. received $1,597.27 in general payments during 2025 across 67 reported records.
AstraZeneca Pharmaceuticals LP accounted for 26.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 256 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Kerendia by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $425.62 | 26.6% | 21 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $242.91 | 15.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $180.25 | 11.3% | 13 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $165.66 | 10.4% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $136.01 | 8.5% | 6 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $101.02 | 6.3% | 4 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $88.74 | 5.6% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $57.32 | 3.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $54.16 | 3.4% | 2 | 2025 |
| Hikma Pharmaceuticals USA | Unresolved — no canonical attribution shown | $38.67 | 2.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.46 | 2.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $27.67 | 1.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $22.36 | 1.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.42 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,597.27 | 67 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $265.27 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $200.49 | 10 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $180.25 | 13 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $146.60 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $113.26 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $113.26 | 5 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $101.02 | 4 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $88.74 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $78.53 | 4 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $57.32 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $54.16 | 2 | 2025 |
Source payment records
|
|||||
| Ryaltris Normalized: ryaltris |
Drug | Hikma Pharmaceuticals USA | $38.67 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $37.46 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $27.67 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.42 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 256 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 91 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 72 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 53 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 86 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
256 | 47 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
72 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
121 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
91 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
86 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 1099 | 152 |
| Atorvastatin Calcium | Atorvastatin Calcium | 952 | 158 |
| Omeprazole | Omeprazole | 770 | 118 |
| Tacrolimus | Tacrolimus | 614 | 64 |
| Metformin Hcl | Metformin Hcl | 551 | 87 |
| Azelastine Hcl | Azelastine Hcl | 444 | 46 |
| Amlodipine Besylate | Amlodipine Besylate | 431 | 73 |
| Montelukast Sodium | Montelukast Sodium | 387 | 60 |
| Carvedilol | Carvedilol | 382 | 52 |
| Simvastatin | Simvastatin | 362 | 50 |
| Levothyroxine Sodium | Levothyroxine Sodium | 357 | 52 |
| Nebivolol Hcl | Nebivolol Hcl | 336 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 303 | 44 |
| Vascepa | Icosapent Ethyl | 302 | 46 |
| Diclofenac Sodium | Diclofenac Sodium | 284 | 51 |
| Farxiga | Dapagliflozin Propanediol | 256 | 47 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 246 | 61 |
| Nifedipine Er | Nifedipine | 223 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 223 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 202 | 36 |
| Clobetasol Propionate | Clobetasol Propionate | 191 | 27 |
| Meclizine Hcl | Meclizine Hcl | 191 | 34 |
| Pregabalin | Pregabalin | 182 | 30 |
| Fluocinonide-E | Fluocinonide/Emollient Base | 165 | 27 |
| Gabapentin | Gabapentin | 149 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 144 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 144 | 25 |
| Ezetimibe | Ezetimibe | 137 | 21 |
| Fluocinonide | Fluocinonide | 137 | 25 |
| Alendronate Sodium | Alendronate Sodium | 134 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 133 | 20 |
| Amoxicillin | Amoxicillin | 132 | 79 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 121 | 23 |
| Tradjenta | Linagliptin | 120 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 119 | 19 |
| Ketoconazole | Ketoconazole | 117 | 17 |
| Finasteride | Finasteride | 115 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 105 | 26 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 104 | 22 |
| Linzess | Linaclotide | 101 | 25 |
| Silver Sulfadiazine | Silver Sulfadiazine | 96 | 17 |
| Jardiance | Empagliflozin | 91 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 91 | 12 |
| Valsartan | Valsartan | 87 | 16 |
| Rybelsus | Semaglutide | 86 | 14 |
| Allopurinol | Allopurinol | 84 | 11 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 84 | suppressed |
| Lisinopril | Lisinopril | 83 | 18 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 78 | 41 |
| Celecoxib | Celecoxib | 74 | 11 |
| Kerendia | Finerenone | 72 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 69 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 13 |
| Nystatin | Nystatin | 62 | 11 |
| Januvia | Sitagliptin Phosphate | 61 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 60 | suppressed |
| Azithromycin | Azithromycin | 59 | 21 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 59 | 16 |
| Famotidine | Famotidine | 59 | 11 |
| Vemlidy | Tenofovir Alafenamide | 58 | suppressed |
| Colchicine | Colchicine | 57 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 57 | suppressed |
| Ozempic | Semaglutide | 53 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 48 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 46 | 11 |
| Hydrocortisone Valerate | Hydrocortisone Valerate | 45 | suppressed |
| Trulicity | Dulaglutide | 45 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 44 | suppressed |
| Glipizide | Glipizide | 44 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 44 | suppressed |
| Gemfibrozil | Gemfibrozil | 41 | suppressed |
| Eliquis | Apixaban | 40 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 39 | suppressed |
| Trulance | Plecanatide | 39 | 12 |
| Propylthiouracil | Propylthiouracil | 35 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 29 | 12 |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Repatha Sureclick | Evolocumab | 28 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 27 | suppressed |
| Procto-Med Hc | Hydrocortisone | 26 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 15 |
| Clonazepam | Clonazepam | 23 | suppressed |
| Furosemide | Furosemide | 23 | suppressed |
| Sotalol | Sotalol Hcl | 23 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 22 | 13 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 22 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Entecavir | Entecavir | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Erythromycin | Erythromycin Base | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Mupirocin | Mupirocin Calcium | 20 | 17 |
| Roflumilast | Roflumilast | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 18 | 14 |
| Atenolol | Atenolol | 17 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Proctozone-Hc | Hydrocortisone | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Nexium | Esomeprazole Magnesium | 15 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 15 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Mitigare | Colchicine | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ultracare Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 13 | suppressed |
| Desoximetasone | Desoximetasone | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,597.27 · 67 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, FARXIGA, IBSRELA, JARDIANCE, Kerendia, Korlym, Ozempic, REXULTI, Ryaltris, Rybelsus, SHINGRIX, The Cologuard Plus Collection Kit, Tymlos, VOQUEZNA | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error